# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Regeneron Pharmaceuticals received a positive opinion from the European Medicines Agency's Committee for Medicinal Products...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the European Medicines Agency's (EMA) Committee for Medi...
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary dis...
Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and maintains $1152 price...
The trial showed a greater proportion of those receiving weight-tiered higher dose Dupixent experienced significant improvement...
Argus Research analyst Jasper Hellweg maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price targ...
Regeneron Pharmaceuticals released data from a Phase 1 study on garetosmab and trevogrumab at the ADA meeting, showing signific...